HUE043998T2 - Eljárás terápiás nanorészecskék elõállítására - Google Patents

Eljárás terápiás nanorészecskék elõállítására

Info

Publication number
HUE043998T2
HUE043998T2 HUE13771005A HUE13771005A HUE043998T2 HU E043998 T2 HUE043998 T2 HU E043998T2 HU E13771005 A HUE13771005 A HU E13771005A HU E13771005 A HUE13771005 A HU E13771005A HU E043998 T2 HUE043998 T2 HU E043998T2
Authority
HU
Hungary
Prior art keywords
therapeutic nanoparticles
preparing therapeutic
preparing
nanoparticles
therapeutic
Prior art date
Application number
HUE13771005A
Other languages
English (en)
Hungarian (hu)
Inventor
Maria Figueiredo
Erick Peeke
David Dewitt
Geen Hoven Christina Van
Greg Troiano
James Wright
Young-Ho Song
Hong Wang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49274868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE043998(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of HUE043998T2 publication Critical patent/HUE043998T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE13771005A 2012-09-17 2013-09-16 Eljárás terápiás nanorészecskék elõállítására HUE043998T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261702037P 2012-09-17 2012-09-17

Publications (1)

Publication Number Publication Date
HUE043998T2 true HUE043998T2 (hu) 2019-09-30

Family

ID=49274868

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13771005A HUE043998T2 (hu) 2012-09-17 2013-09-16 Eljárás terápiás nanorészecskék elõállítására

Country Status (22)

Country Link
US (1) US9877923B2 (https=)
EP (1) EP2895156B1 (https=)
JP (1) JP6356678B2 (https=)
KR (1) KR20150056618A (https=)
CN (1) CN104812381B (https=)
AU (1) AU2013315118B2 (https=)
BR (1) BR112015005940A2 (https=)
CA (1) CA2885193C (https=)
DK (1) DK2895156T3 (https=)
EA (1) EA032943B1 (https=)
ES (1) ES2732377T3 (https=)
HU (1) HUE043998T2 (https=)
IL (1) IL237780A0 (https=)
MX (1) MX356097B (https=)
MY (1) MY179194A (https=)
NZ (1) NZ705812A (https=)
PL (1) PL2895156T3 (https=)
PT (1) PT2895156T (https=)
SG (1) SG11201502065UA (https=)
SI (1) SI2895156T1 (https=)
TR (1) TR201909389T4 (https=)
WO (1) WO2014043618A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2721850T3 (es) 2008-06-16 2019-08-05 Pfizer Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
JP2012501965A (ja) 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
WO2010068866A2 (en) 2008-12-12 2010-06-17 Bind Biosciences Therapeutic particles suitable for parenteral administration and methods of making and using same
US20100216804A1 (en) 2008-12-15 2010-08-26 Zale Stephen E Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
US8357401B2 (en) 2009-12-11 2013-01-22 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
ES2780156T3 (es) 2009-12-15 2020-08-24 Pfizer Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
MX356097B (es) 2012-09-17 2018-05-14 Pfizer Inc Star Proceso para la preparacion de nanoparticulas terapeuticas.
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
ES2640648T3 (es) 2013-09-16 2017-11-03 Astrazeneca Ab Nanopartículas poliméricas terapéuticas y métodos para su fabricación y uso
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
SI3104838T1 (sl) 2014-02-13 2020-04-30 Pfizer Inc. Terapevtski nanodelci, ki vsebujejo terapevtsko sredstvo, in postopki za izdelovanje in uporabo omenjenih nanodelcev
MA39734B1 (fr) 2014-03-14 2019-07-31 Pfizer Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation
KR20180112060A (ko) 2016-02-23 2018-10-11 타베다 세라퓨틱스, 인코포레이티드 Hsp90 표적화된 접합체 및 이의 입자 및 제형
EP3432864B1 (en) * 2016-03-22 2020-05-06 Pfizer Inc Process for preparing therapeutic nanoparticles
US11786607B2 (en) 2017-06-15 2023-10-17 Modernatx, Inc. RNA formulations
TWI717629B (zh) * 2017-08-28 2021-02-01 大陸商江蘇恒瑞醫藥股份有限公司 Cyp17抑制劑的藥物組合物及其製備方法
WO2019046809A1 (en) 2017-08-31 2019-03-07 Modernatx, Inc. METHODS OF MANUFACTURING LIPID NANOPARTICLES
CN113292537B (zh) * 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
CN113271926A (zh) 2018-09-20 2021-08-17 摩登纳特斯有限公司 脂质纳米颗粒的制备及其施用方法
EP4055032A1 (en) * 2019-11-07 2022-09-14 The Board Of Trustees Of The University Of Illinois Peptides and methods of treating sepsis, atherosclerosis, thrombosis, stroke, heart attack and inflammation
MX2023003556A (es) 2020-09-29 2023-06-13 Shenzhen Pharmacin Co Ltd Composiciones farmaceuticas.
US11833224B1 (en) 2023-02-08 2023-12-05 Leuvian Llc Lyoprotectant compositions and uses thereof

Family Cites Families (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3852037T2 (de) 1987-07-29 1995-03-23 Liposome Co Inc Verfahren zur trennung von teilchen nach grösse.
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5766635A (en) 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
AU3095092A (en) 1991-12-09 1993-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
GB9412273D0 (en) 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
EP0805678B1 (en) 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Surface-modified nanoparticles and method of making and using same
ATE201983T1 (de) 1995-03-10 2001-06-15 Roche Diagnostics Gmbh Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung
US6902743B1 (en) 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
JP2942508B2 (ja) 1997-01-14 1999-08-30 順也 藤森 温度感受性徐放性基剤及び温度感受性徐放性システム
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6254890B1 (en) 1997-12-12 2001-07-03 Massachusetts Institute Of Technology Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
WO2000000222A1 (en) 1998-06-30 2000-01-06 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of biologically active agents
US6265609B1 (en) 1998-07-06 2001-07-24 Guilford Pharmaceuticals Inc. Thio-substituted pentanedioic acid derivatives
US6395718B1 (en) 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
KR100274842B1 (ko) 1998-10-01 2001-03-02 김효근 미립구를 이용한 레티노익산의 서방형 약물방출 시스템
DE19856432A1 (de) 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
FI982733L (fi) * 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US6528499B1 (en) 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
CA2321321A1 (en) 1999-09-30 2001-03-30 Isotis B.V. Polymers loaded with bioactive agents
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US20050037086A1 (en) 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
KR100416242B1 (ko) 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
US6890946B2 (en) 1999-12-23 2005-05-10 Indiana University Research And Technology Corporation Use of parthenolide to inhibit cancer
US7217770B2 (en) 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
KR100418916B1 (ko) 2000-11-28 2004-02-14 한국과학기술원 생분해성 고분자와 항암제의 접합체를 이용한 서방형미셀제제의 제조방법
KR100446101B1 (ko) 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
EP1343478B1 (en) 2000-12-21 2007-10-10 Alrise Biosystems GmbH Induced phase transition method for the production of microparticles containing hydrophilic active agents
US6623761B2 (en) 2000-12-22 2003-09-23 Hassan Emadeldin M. Method of making nanoparticles of substantially water insoluble materials
DK1345597T3 (da) 2000-12-27 2007-12-10 Ares Trading Sa Amfifile lipidanopartikler til peptid- og/eller proteininkorporering
WO2002098885A1 (en) 2001-02-07 2002-12-12 Beth Israel Deaconess Medical Center Modified psma ligands and uses related thereto
AU2002338336A1 (en) 2001-04-03 2002-10-21 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
CA2451185A1 (en) 2001-06-21 2003-01-03 Altus Biologics, Inc. Spherical protein particles and methods of making and using them
CN1325046C (zh) 2001-08-31 2007-07-11 麦吉尔大学 可生物降解的多聚纳米微囊及其应用
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
BRPI0213226B1 (pt) 2001-10-10 2016-03-01 Pf Medicament processo de preparação de uma composição farmacêutica sob forma de microesferas com liberação prolongada de um princípio ativo hidrossolúvel, e, microesferas
WO2003032906A2 (en) 2001-10-15 2003-04-24 Crititech, Inc. Delivery of poorly soluble drugs
US20030235619A1 (en) 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
US20060177495A1 (en) 2001-12-21 2006-08-10 Christine Allen Polymer-lipid delivery vehicles
AU2003205077A1 (en) 2002-01-10 2003-07-30 Johns Hopkins University Imaging agents and methods of imaging naaladase of psma
US20060165987A1 (en) 2002-04-05 2006-07-27 Patrice Hildgen Stealthy polymeric biodegradable nanospheres and uses thereof
US20030232887A1 (en) 2002-04-10 2003-12-18 Johnson Douglas Giles Preparation and use of a stable formulation of allosteric effector compounds
WO2003090710A1 (en) 2002-04-23 2003-11-06 Case Western Reserve University Lapachone delivery systems, compositions and uses related thereto
JP2003342168A (ja) 2002-05-24 2003-12-03 Nano Career Kk 注射用薬物含有ポリマーミセル製剤の製造方法
KR20050037992A (ko) 2002-06-05 2005-04-25 유니버시티 오브 플로리다 안약 전달 장치
US7767803B2 (en) 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
JP4530626B2 (ja) * 2002-06-25 2010-08-25 武田薬品工業株式会社 徐放性組成物の製造方法
US7879351B2 (en) 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
EP1569620A4 (en) 2002-10-30 2006-03-22 Spherics Inc NANOPARTICULAR BIOACTIVE AGENTS
JP4917263B2 (ja) 2002-12-23 2012-04-18 バイカル インコーポレイテッド 核酸／ブロックコポリマー／陽イオン性界面活性剤複合体を凍結乾燥する方法
US6841547B2 (en) 2003-02-28 2005-01-11 Albert Einstein College Of Medicine Of Yeshevia University Method for decreasing low density lipoprotein
US20040185170A1 (en) 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
EP1610768B1 (en) 2003-03-26 2008-07-02 Egalet A/S Matrix compositions for controlled delivery of drug substances
EP1594482A1 (en) 2003-03-26 2005-11-16 LTT Bio-Pharma Co., Ltd. Intravenous nanoparticles for targeting drug delivery and sustained drug release
EP1608359A4 (en) 2003-04-03 2011-08-17 Jessie L-S Au DRUG-LOADING PARTICLES TARGETING TUMORS
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20050256071A1 (en) 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
WO2005007122A2 (en) * 2003-07-18 2005-01-27 Oakwood Laboratories, L.L.C. Polymer stabilization
US20050142205A1 (en) 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
WO2005009357A2 (en) 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
AU2004268377B2 (en) 2003-09-02 2008-06-26 Novartis Ag Cancer treatment with epothilones
US7311901B2 (en) 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
US7846412B2 (en) 2003-12-22 2010-12-07 Emory University Bioconjugated nanostructures, methods of fabrication thereof, and methods of use thereof
US20070053845A1 (en) 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
JP2007526322A (ja) 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
US8043631B2 (en) 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
US20080124400A1 (en) 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
JP2008512350A (ja) 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
JP2006131577A (ja) 2004-11-09 2006-05-25 Ltt Bio-Pharma Co Ltd 異なる粒子径を有する薬物封入ナノ粒子の作製方法および当該方法で得られたナノ粒子
EP1830902A2 (en) 2004-12-30 2007-09-12 Cinvention Ag Combination comprising an agent providing a signal, an implant material and a drug
WO2006093991A1 (en) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
CA2603081C (en) 2005-04-04 2013-09-03 Sinexus, Inc. Device and methods for treating paranasal sinus conditions
JP2006321763A (ja) 2005-05-20 2006-11-30 Hosokawa Funtai Gijutsu Kenkyusho:Kk 生体適合性ナノ粒子及びその製造方法
MX2007016039A (es) 2005-06-17 2008-10-27 Univ North Carolina Metodos, sistemas y materiales de fabricacion de nanoparticulas.
KR20080031379A (ko) 2005-07-11 2008-04-08 와이어쓰 글루타메이트 아그레카나제 저해제
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
AU2006284657B2 (en) 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
JP2009507049A (ja) 2005-09-09 2009-02-19 北京徳科瑞医薬科技有限公司 リン脂質のポリエチレングリコール誘導体に包み込まれたビンカアルカロイド系制癌剤のナノミセル製剤
US20090022806A1 (en) * 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
AU2006293410B2 (en) 2005-09-20 2012-10-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Nanoparticles for targeted delivery of active agents
US8916206B2 (en) 2005-12-26 2014-12-23 Ltt Bio-Pharma Co., Ltd. Nanoparticles containing water-soluble non-peptide low-molecular weight drug
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
KR20090006062A (ko) 2006-02-23 2009-01-14 에리모스 파마슈티컬스 엘엘씨 인플루엔자 바이러스 감염의 치료 방법
DE102006013531A1 (de) 2006-03-24 2007-09-27 Lts Lohmann Therapie-Systeme Ag Polylactid-Nanopartikel
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
JP5373606B2 (ja) 2006-07-26 2013-12-18 サンド・アクチエンゲゼルシヤフト カスポファンギン製剤
US20080145439A1 (en) 2006-07-31 2008-06-19 Neurosystec Corporation Nanoparticle drug formulations
BRPI0714782A2 (pt) 2006-07-31 2013-07-16 Senju Pharma Co preparaÇço lÍquida aquosa contendo composto de amida
US20100144845A1 (en) 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
US9248121B2 (en) 2006-08-21 2016-02-02 Abbott Laboratories Medical devices for controlled drug release
US20100008998A1 (en) 2006-09-26 2010-01-14 Samyang Corporation Submicron nanoparticle of poorly water soluble camptothecin derivatives and process for preparation thereof
ES2847275T3 (es) 2006-11-08 2021-08-02 Molecular Insight Pharm Inc Heterodímeros de ácido glutámico
WO2008147456A2 (en) 2006-11-20 2008-12-04 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
CN1957911A (zh) 2006-12-01 2007-05-09 济南康泉医药科技有限公司 一种抗实体肿瘤缓释剂
CN101396342A (zh) 2006-12-12 2009-04-01 济南帅华医药科技有限公司 含埃坡霉素衍生物的抗癌缓释注射剂
CN101396340A (zh) 2006-12-12 2009-04-01 济南帅华医药科技有限公司 一种含埃坡霉素衍生物的抗癌缓释注射剂
CN1969818A (zh) 2006-12-12 2007-05-30 济南帅华医药科技有限公司 一种含埃坡霉素衍生物的抗癌缓释注射剂
CN1969816A (zh) 2006-12-12 2007-05-30 济南帅华医药科技有限公司 一种含埃坡霉素的抗癌缓释剂
CN101433520A (zh) 2006-12-12 2009-05-20 济南帅华医药科技有限公司 含埃坡霉素的抗癌缓释剂
CN1961864A (zh) 2006-12-12 2007-05-16 济南帅华医药科技有限公司 一种抗癌的组合物
WO2008091465A2 (en) 2006-12-21 2008-07-31 Wayne State University Peg and targeting ligands on nanoparticle surface
WO2008109163A1 (en) 2007-03-07 2008-09-12 Abraxis Bioscience, Llc. Nanoparticle comprising rapamycin and albumin as anticancer agent
CN101053553B (zh) 2007-03-16 2011-04-20 吉林大学 一种生物可降解氟尿嘧啶聚酯载药纳米球及其制备方法
EP2136788B1 (en) 2007-03-30 2011-10-26 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
WO2008124632A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
CN101678113B (zh) 2007-05-14 2012-05-30 日本株式会社Ltt生物医药 缓释性的含有带负电荷基团的低分子药物的纳米粒子
WO2008151245A1 (en) 2007-06-04 2008-12-11 Sun Chemical Corporation Dispersions for plastic films
CA3076115C (en) 2007-08-21 2022-06-28 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
US20090061009A1 (en) 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
US20090306120A1 (en) 2007-10-23 2009-12-10 Florencia Lim Terpolymers containing lactide and glycolide
US8974814B2 (en) 2007-11-12 2015-03-10 California Institute Of Technology Layered drug delivery polymer monofilament fibers
WO2009070302A1 (en) 2007-11-30 2009-06-04 The Johns Hopkins University Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
WO2009084801A1 (en) 2007-12-31 2009-07-09 Samyang Corporation Amphiphilic block copolymer micelle composition containing taxane and manufacturing process of the same
EP2106806A1 (en) 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung
US20090312402A1 (en) 2008-05-20 2009-12-17 Contag Christopher H Encapsulated nanoparticles for drug delivery
WO2010005740A2 (en) 2008-06-16 2010-01-14 Bind Biosciences, Inc. Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
CN102099016A (zh) * 2008-06-16 2011-06-15 佰恩德生物科学股份有限公司 载药的聚合物纳米微粒及其制备和使用方法
ES2721850T3 (es) 2008-06-16 2019-08-05 Pfizer Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
JP2012501965A (ja) 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
WO2010006059A1 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 binding proteins and uses thereof
US20100087337A1 (en) 2008-09-10 2010-04-08 Bind Biosciences, Inc. High Throughput Fabrication of Nanoparticles
US20110125090A1 (en) 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
WO2010068866A2 (en) 2008-12-12 2010-06-17 Bind Biosciences Therapeutic particles suitable for parenteral administration and methods of making and using same
US20100216804A1 (en) 2008-12-15 2010-08-26 Zale Stephen E Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
WO2010114768A1 (en) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
WO2010114770A1 (en) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
CN103932972A (zh) 2009-03-30 2014-07-23 天蓝制药公司 聚合物-药剂缀合物、颗粒、组合物和相关使用方法
HUE032426T2 (en) 2009-05-27 2017-09-28 Alkermes Pharma Ireland Ltd Inhibition of flake aggregation in nanoparticulate meloxicam formulations
US7772274B1 (en) * 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8357401B2 (en) 2009-12-11 2013-01-22 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
ES2780156T3 (es) 2009-12-15 2020-08-24 Pfizer Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular
JP6175237B2 (ja) 2009-12-15 2017-08-02 ファイザー・インク コルチコステロイドを含む治療用ポリマーナノ粒およびそれを製造かつ使用する方法
JP5898627B2 (ja) 2009-12-15 2016-04-06 バインド セラピューティックス インコーポレイテッド エポチロンを含む治療用ポリマーナノ粒子ならびにそれを製造および使用する方法
WO2011079279A2 (en) 2009-12-23 2011-06-30 Board Of Trustees Of The University Of Illinois Nanoconjugates and nanoconjugate formulations
US20110237686A1 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc Formulations and methods of use
WO2012040513A1 (en) * 2010-09-22 2012-03-29 The Board Of Regents Of The University Of Texas System Compositions and methods for the delivery of beta lapachone
EP2629760A4 (en) * 2010-10-22 2014-04-02 Bind Therapeutics Inc THERAPEUTIC NANOPARTICLES CONTAINING COPOLYMERS OF HIGH MOLECULAR WEIGHT
WO2012166923A2 (en) 2011-05-31 2012-12-06 Bind Biosciences Drug loaded polymeric nanoparticles and methods of making and using same
EP2747761A1 (en) 2011-09-22 2014-07-02 Bind Therapeutics, Inc. Methods of treating cancers with therapeutic nanoparticles
EP2802314B1 (en) 2012-01-13 2020-11-25 XSpray Microparticles AB A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
ES2685743T3 (es) * 2012-02-29 2018-10-11 Merck Patent Gmbh Procedimiento para la fabricación de nanopartículas cargadas con principio activo
MX356097B (es) 2012-09-17 2018-05-14 Pfizer Inc Star Proceso para la preparacion de nanoparticulas terapeuticas.
BR112015005878A2 (pt) 2012-09-17 2017-07-04 Bind Therapeutics Inc nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas

Also Published As

Publication number Publication date
JP2015528510A (ja) 2015-09-28
SG11201502065UA (en) 2015-05-28
AU2013315118A1 (en) 2015-04-02
DK2895156T3 (da) 2019-07-15
EA032943B1 (ru) 2019-08-30
WO2014043618A1 (en) 2014-03-20
EA201590583A1 (ru) 2015-11-30
EP2895156B1 (en) 2019-05-08
NZ705812A (en) 2018-08-31
CA2885193A1 (en) 2014-03-20
MY179194A (en) 2020-10-30
PT2895156T (pt) 2019-06-28
HK1211470A1 (en) 2016-05-27
EP2895156A1 (en) 2015-07-22
IL237780A0 (en) 2015-05-31
AU2013315118B2 (en) 2017-10-05
CA2885193C (en) 2021-04-27
SI2895156T1 (sl) 2019-08-30
CN104812381A (zh) 2015-07-29
KR20150056618A (ko) 2015-05-26
MX356097B (es) 2018-05-14
TR201909389T4 (tr) 2019-07-22
US9877923B2 (en) 2018-01-30
PL2895156T3 (pl) 2019-09-30
MX2015003405A (es) 2015-06-05
JP6356678B2 (ja) 2018-07-11
CN104812381B (zh) 2018-01-26
US20140186452A1 (en) 2014-07-03
ES2732377T3 (es) 2019-11-22
BR112015005940A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
IL237780A0 (en) A process for the preparation of medical nanoparticles
IL235826A (en) Diazaspirocycloalkanes and thenaspirocycloalkanes and their preparation
ZA201500603B (en) Process
GB201216921D0 (en) Process
EP2839940A4 (en) METHOD FOR PRODUCING A BODY FORMED FROM CONCRETE
GB201207997D0 (en) Process
IL233985A0 (en) Process for the production of nanoparticles
GB201214326D0 (en) Process
GB201213360D0 (en) Process
PL2890639T3 (pl) Nowy sposób wytwarzania strącanej krzemionki
GB201219224D0 (en) Process
PL399419A1 (pl) Sposób wytwarzania 4-metoksydihydrochalkonu
PL399418A1 (pl) Sposób wytwarzania 4-metoksydihydrochalkonu
IL236450A0 (en) Process for the preparation of 5-fluoro-h1-pyrazoles
EP2852660A4 (en) PROCESS
GB201219960D0 (en) Process
ZA201407214B (en) Therapeutic preparation and process for preparing said therapeutic preparation
GB201218078D0 (en) Process
IL233626A0 (en) A process for the preparation of chloroamines
IL233388A (en) Process for the preparation of acetanilides
GB201216653D0 (en) Process
EP2831054A4 (en) IMPROVED PROCESS FOR THE PRODUCTION OF (S) -EQUOL
IL236126A0 (en) Process for preparing 4-cyclohexyl-2-methyl-2-butanol
GB201205449D0 (en) Treatment process
HUP1200675A2 (en) Process for the preparation of pyrimidinyl-piperazines